Why are Metrics Important in Starting Clinical Trials?
We now operate in a data driven environment
This question may seem counter intuitive, as we are exposed almost daily to the dire performance of clinical trials and their spiraling costs resulting from incurred delays. Metrics are indeed critical to efforts to rein in clinical trials that are either poorly initiated or have incurred unforeseen events which place the original timelines and/or budgets at risk of overages. They also drive competitive performance among those organizations performing trials. But how? The webinar will focus on these issues and the competitive edge metrics provide those organizations engaged in conducting clinical trials.
In this webinar we will explore:
- Business Intelligence: The need to make smarter decisions on intelligences derived from clinical trial data
- Industry trends on data mining and analytics
- The need for industry benchmarking across trials & its inherent challenges
- Moving beyond benchmarking to gamification, efficient resource allocation, and predicative analytics or forecasting
This webinar is applicable to:
- Sponsor and CRO roles responsible for site selection and activation
- Sponsor and CRO roles responsible for collecting and evaluating trial metrics
Jeff Kasher is a known pharmaceutical development change expert with 28 years of experience at Eli Lilly. He is passionate for improving outcomes, bringing patients and research sites into the development process, and dramatically decreasing time to market. His expertise includes novel product development from bench through market launch, research and clinical trial leadership, innovation center start up as well as new industry paradigm creation.
Jeff is President of Patients Can't Wait, Chairman of Advisory Board for DrugDev as well as member of Advisory Board of TrialReach, Cytolon, and goBalto. He sits on the DPharm steering committee and faculty, and is a member of Linking Leaders. In 2013 CenterWatch Jeff was named one of the "20 Innovators Changing the Face of the Clinical Trials Industry." He received a B.S. in Chemistry from Franklin & Marshall College, a Ph.D. in Pharmacology from the State University of New York, and a Post-Doctoral Fellowship in Physiology at Yale University School of Medicine.
Patients Can't Wait
Ms. Sullivan is Co-Founder and President of the Metrics Champion Consortium (MCC), an industry association dedicated to leading the drug-development enterprise in the adoption and utilization of standardized metrics and benchmarks to drive performance improvement. She has been a featured speaker at Performance Metrics, Risk-Based Monitoring, Quality Management and Clinical Trial Oversight industry meetings.
Ms. Sullivan received a B.S. in biology from Trinity College and a M.B.A. from Dartmouth College, where she was named a Tuck Scholar.
Co-Founder and President
Metrics Champion Consortium
Rob has been a computer scientist and programmer for over 30 years in the scientific programming, e-commerce, biotech, and health care industries. He implemented study startup and CTMS functionality at 9 bay area biotech companies, and invented a method that allows medical and biotech organizations to use cloud-based analytics to monitor patient data. He holds a BS in Computer Engineering from Sacramento State University and a PhD in Biological and Biomedical Clinical Informatics from UCSF.
VP Technology & Engineering
Need more information?
Contact us with your questions or to schedule a demo.